Evidence map›Paper›PMID 36293329›Full record

ArticleInternational journal of molecular sciences2022

TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.

Céline Chevaleyre, Dimitri Kereselidze, Fabien Caillé, Nicolas Tournier, Nagore G Olaciregui, Alexandra Winkeler, Xavier Declèves, Benoit Jego, Salvatore Cisternino, Sylvain Auvity and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Céline ChevaleyreBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.
Dimitri KereselidzeBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.
Fabien CailléBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.ORCID 0000-0003-0088-7337
Nicolas TournierBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.ORCID 0000-0002-0755-2030
Nagore G OlacireguiInstitut de Recerca, Sant Joan de Déu Hospital, Carrer de Sant Quinti, 77, 08041 Barcelona, Spain.
Alexandra WinkelerBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.ORCID 0000-0003-3397-2570
Xavier DeclèvesInserm UMR-S1144, University of Paris Cité, 75006 Paris, France.ORCID 0000-0002-9526-2294
Benoit JegoBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.
Salvatore CisterninoInserm UMR-S1144, University of Paris Cité, 75006 Paris, France.ORCID 0000-0001-8500-3574
Sylvain AuvityBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.
Charles TruilletBioMaps, Service Hospitalier Frédéric Joliot, CEA, CNRS, Inserm, University of Paris-Saclay, 4 Place du Général Leclerc, 91401 Orsay, France.
Centre National de la Recherche Scientifique · FRHôpital Necker-Enfants Malades · FRHospital Sant Joan de Déu Barcelona · ESInserm · FR

Funding

Agence Nationale de la Recherche ANR-11-INBS-0006Atomic Energy and Alternative Energies Commission "Bottom up" Grant REGIME
6 · The paper itself

Abstract

Diffuse intrinsic pontine gliomas (DIPG), the first cause of cerebral pediatric cancer death, will greatly benefit from specific and non-invasive biomarkers for patient follow-up and monitoring of drug efficacy. Since biopsies are challenging for brain tumors, molecular imaging may be a technique of choice to target and follow tumor evolution. So far, MR remains the imaging technique of reference for DIPG, although it often fails to define the extent of tumors, an essential parameter for therapeutic efficacy assessment. Thanks to its high sensitivity, positron emission tomography (PET) offers a unique way to target specific biomarkers in vivo. We demonstrated in a patient-derived orthotopic xenograft (PDOX) model in the rat that the translocator protein of 18 kDa (TSPO) may be a promising biomarker for monitoring DIPG tumors. We studied the distribution of 18F-DPA-714, a TSPO radioligand, in rats inoculated with HSJD-DIPG-007 cells. The primary DIPG human cell line HSJD-DIPG-007 highly represents this pediatric tumor, displaying the most prevalent DIPG mutations, H3F3A (K27M) and ACVR1 (R206H). Kinetic modeling and parametric imaging using the brain 18F-DPA-714 PET data enabled specific delineation of the DIPG tumor area, which is crucial for radiotherapy dose management.

Indexed as

AstrocytomaBrain Stem NeoplasmsDiffuse Intrinsic Pontine GliomaGliomaAnimalsBiomarkersCarrier ProteinsCell Line, TumorChildDisease Models, AnimalHumansPositron-Emission TomographyRatsReceptors, GABAReceptors, GABA-ABiomarkersCarrier ProteinsReceptors, GABAReceptors, GABA-ATSPO protein, humanTspo protein, ratDIPG biomarkerPDOXTSPO-PET imaging

Identifiers

PMID36293329
PMCPMC9603997
OpenAlexW4306742559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.